JPM 2022: J&J, Legend hope to avoid supply challenges that have ailed Bristol Myers’ Abecma as cilta-cel nears FDA nodnews2022-01-11T20:23:13+00:00January 11th, 2022|Fierce Pharma|
JPM 2022: Sanofi has designs on creating Big Pharma’s ‘strongest’ immunology franchise, CFO saysnews2022-01-11T20:04:57+00:00January 11th, 2022|Fierce Pharma|
JPM 2022: Amgen dials up biosimilar ambitions, with at least $4B in expected sales by 2030news2022-01-11T19:29:00+00:00January 11th, 2022|Fierce Pharma|
Endo pivots its Dupuytren’s campaign from John Elway to a patient-led pitchnews2022-01-11T17:54:39+00:00January 11th, 2022|Fierce Pharma|
JPM 2022: What FDA crackdown? Novartis oncology chief touts BeiGene PD-1’s global profilenews2022-01-11T16:06:51+00:00January 11th, 2022|Fierce Pharma|
China CDMO group ZhenGe Biotech raises $100M in series C financingnews2022-01-11T14:59:30+00:00January 11th, 2022|Fierce Pharma|
JPM 2022: How Novavax plans to be a COVID-19 vaccine force in 2022news2022-01-11T14:31:10+00:00January 11th, 2022|Fierce Pharma|
Selecta taps Ginkgo to create better capsids for gene therapy delivery news2022-01-11T14:27:13+00:00January 11th, 2022|Fierce Pharma|
Kyowa sells U.S. rights to cancer drug delivery patch to Cumberlandnews2022-01-11T14:22:51+00:00January 11th, 2022|Fierce Pharma|
South Korea’s SK commits $350M to help build global cell and gene therapy CDMOnews2022-01-11T13:45:20+00:00January 11th, 2022|Fierce Pharma|
